Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy

Monica Verdoia; Patrizia Pergolini; Roberta ROLLA; Matteo Nardin; Lucia Barbieri; Veronica Daffara; Paolo MARINO; Giorgio BELLOMO; Harry Suryapranata; GIUSEPPE DE LUCA

doi:10.1007/s10557-016-6646-5

Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy

Monica Verdoia, Patrizia Pergolini, Roberta ROLLA, Matteo Nardin, Lucia Barbieri, Veronica Daffara, Paolo MARINO, Giorgio BELLOMO, Harry Suryapranata, GIUSEPPE DE LUCA

Dipartimento di Scienze della Salute

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Cardiovascular risk is still underestimated in women, experiencing higher mortality and worse prognosis after acute cardiovascular events. Gender differences have been reported in thrombotic and hemorrhagic risk during dual antiplatelet therapy (DAPT), thus suggesting a potential variability in platelet reactivity according to sex. The aim of the present study was to assess the role of gender on platelet function and the prevalence of high-on treatment residual platelet reactivity (HRPR) during DAPT in patients with recent acute coronary syndrome or percutaneous coronary revascularization.

Lingua originale	Inglese
pagine (da-a)	143-150
Numero di pagine	8
Rivista	Cardiovascular Drugs and Therapy
Volume	30
Numero di pubblicazione	2
DOI	https://doi.org/10.1007/s10557-016-6646-5
Stato di pubblicazione	Pubblicato - 2016

Keywords

Clopidogrel
Coronary artery disease
Dual antiplatelet therapy
Gender
Platelet aggregation
Ticagrelor

Accesso al documento

10.1007/s10557-016-6646-5

http://hdl.handle.net/11579/75750

Altri file e collegamenti

handle

Cita questo

@article{38b9fb0cb3fd4b74a999c6f555bec1b2,

title = "Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy",

abstract = "Cardiovascular risk is still underestimated in women, experiencing higher mortality and worse prognosis after acute cardiovascular events. Gender differences have been reported in thrombotic and hemorrhagic risk during dual antiplatelet therapy (DAPT), thus suggesting a potential variability in platelet reactivity according to sex. The aim of the present study was to assess the role of gender on platelet function and the prevalence of high-on treatment residual platelet reactivity (HRPR) during DAPT in patients with recent acute coronary syndrome or percutaneous coronary revascularization.",

keywords = "Clopidogrel, Coronary artery disease, Dual antiplatelet therapy, Gender, Platelet aggregation, Ticagrelor, Clopidogrel, Coronary artery disease, Dual antiplatelet therapy, Gender, Platelet aggregation, Ticagrelor",

author = "Monica Verdoia and Patrizia Pergolini and Roberta ROLLA and Matteo Nardin and Lucia Barbieri and Veronica Daffara and Paolo MARINO and Giorgio BELLOMO and Harry Suryapranata and {DE LUCA}, GIUSEPPE",

note = "Publisher Copyright: {\textcopyright} 2016, Springer Science+Business Media New York.",

year = "2016",

doi = "10.1007/s10557-016-6646-5",

language = "English",

volume = "30",

pages = "143--150",

journal = "Cardiovascular Drugs and Therapy",

issn = "1573-7241",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy

AU - Verdoia, Monica

AU - Pergolini, Patrizia

AU - ROLLA, Roberta

AU - Nardin, Matteo

AU - Barbieri, Lucia

AU - Daffara, Veronica

AU - MARINO, Paolo

AU - BELLOMO, Giorgio

AU - Suryapranata, Harry

AU - DE LUCA, GIUSEPPE

PY - 2016

Y1 - 2016

N2 - Cardiovascular risk is still underestimated in women, experiencing higher mortality and worse prognosis after acute cardiovascular events. Gender differences have been reported in thrombotic and hemorrhagic risk during dual antiplatelet therapy (DAPT), thus suggesting a potential variability in platelet reactivity according to sex. The aim of the present study was to assess the role of gender on platelet function and the prevalence of high-on treatment residual platelet reactivity (HRPR) during DAPT in patients with recent acute coronary syndrome or percutaneous coronary revascularization.

AB - Cardiovascular risk is still underestimated in women, experiencing higher mortality and worse prognosis after acute cardiovascular events. Gender differences have been reported in thrombotic and hemorrhagic risk during dual antiplatelet therapy (DAPT), thus suggesting a potential variability in platelet reactivity according to sex. The aim of the present study was to assess the role of gender on platelet function and the prevalence of high-on treatment residual platelet reactivity (HRPR) during DAPT in patients with recent acute coronary syndrome or percutaneous coronary revascularization.

KW - Clopidogrel

KW - Coronary artery disease

KW - Dual antiplatelet therapy

KW - Gender

KW - Platelet aggregation

KW - Ticagrelor

KW - Clopidogrel

KW - Coronary artery disease

KW - Dual antiplatelet therapy

KW - Gender

KW - Platelet aggregation

KW - Ticagrelor

UR - https://iris.uniupo.it/handle/11579/75750

U2 - 10.1007/s10557-016-6646-5

DO - 10.1007/s10557-016-6646-5

M3 - Article

SN - 1573-7241

VL - 30

SP - 143

EP - 150

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

IS - 2

ER -

Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo